個別化医療バイオマーカーの世界市場レポート 2025年

個別化医療バイオマーカー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.6％で515億3,000万米ドルに成長します。予測期間中の成長は、プレシジョン・オンコロジーにおけるバイオマーカーの応用拡大、標的治療に対する需要の高まり、疾病の早期発見への注目の高まり、個別化アプローチに対する消費者の需要の高まり、政府の支援政策と資金提供によるものと考えられます。予測期間に予想される主な動向には、バイオマーカー同定におけるマルチオミクスアプローチの採用、リキッドバイオプシーに基づくバイオマーカーの開発、デジタルバイオマーカーの利用の拡大、バイオマーカー探索におけるAIと機械学習の統合、バイオマーカー検証における実世界エビデンスの拡大などがあります。

慢性疾患の有病率の増加は、個別化医療バイオマーカー市場の大幅な成長を促進すると予想されます。慢性疾患は、徐々に発症し長期間持続する長期的な疾患であり、多くの場合、継続的な医療を必要としたり、日常生活に影響を及ぼしたりします。慢性疾患の増加は、不健康なライフスタイルの選択、食生活の乱れ、運動不足、高いストレスレベルが主な原因です。個別化医療バイオマーカーは、個人の遺伝子や分子プロファイルに基づいて治療を調整することにより、これらの疾患を管理する上で重要な役割を果たしています。これらのバイオマーカーは、最も効果的な治療法を特定し、病気の進行を予測し、副作用を最小限に抑えるのに役立ちます。例えば、世界保健機関（WHO）は、2050年までに新たながん患者数が3,500万人を超え、2022年から77％増加すると予測しています。このような慢性疾患の蔓延は、個別化医療バイオマーカーの需要を加速させています。

個別化医療バイオマーカー市場の企業は、製品の信頼性を高め、市場範囲を拡大し、患者の転帰を改善するために、規制当局の承認取得に注力しています。規制当局の承認は、医療製品、治療、技術が安全性、有効性、品質基準を満たしていることを保証するために不可欠です。例えば、2024年8月、米国のバイオテクノロジー企業であるIllumina, Inc.は、がんバイオマーカー検査と2つのコンパニオン診断薬についてFDAの承認を取得しました。この検査は次世代シーケンサー（NGS）技術を用いてがん細胞の遺伝子変異を同定し、臨床医が個々のバイオマーカーに基づいて最適な治療を選択できるようにするものです。今回の承認はプレシジョン・オンコロジーにおける重要なマイルストーンであり、治療選択のスピードと精度を向上させ、がん患者に対する個別化治療を強化するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の個別化医療バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の個別化医療バイオマーカー市場：成長率分析
• 世界の個別化医療バイオマーカー市場の実績：規模と成長、2019年～2024年
• 世界の個別化医療バイオマーカー市場の予測：規模と成長、2024年～2029年、2034年
• 世界の個別化医療バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の個別化医療バイオマーカー市場：バイオマーカータイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• ゲノム
• プロテオミクス
• 代謝
• その他のバイオマーカーの種類
• 世界の個別化医療バイオマーカー市場：疾患適応症別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 腫瘍学
• 神経学
• 糖尿病
• 自己免疫疾患
• 心臓病学
• その他の適応症
• 世界の個別化医療バイオマーカー市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 早期発見またはスクリーニング
• 診断
• 治療の選択
• モニタリング
• 世界の個別化医療バイオマーカー市場：最終用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院と診療所
• 製薬およびバイオテクノロジー企業
• 診断ラボ
• その他のエンドユーザー
• 世界の個別化医療バイオマーカー市場、ゲノムのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 一塩基多型（SNP）
• コピー数変異（CNV）
• 遺伝子発現バイオマーカー
• エピジェネティックバイオマーカー
• 世界の個別化医療バイオマーカー市場、プロテオミクスの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• タンパク質発現バイオマーカー
• 翻訳後修飾（PTM）バイオマーカー
• タンパク質間相互作用バイオマーカー
• 酵素活性バイオマーカー
• 世界の個別化医療バイオマーカー市場、代謝のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 脂質バイオマーカー
• アミノ酸バイオマーカー
• 炭水化物バイオマーカー
• ホルモンバイオマーカー
• 世界の個別化医療バイオマーカー市場、その他のバイオマーカータイプのサブセグメンテーション（タイプ別）、実績と予測、2019年～2024年、2024年～2029年、2034年
• 炎症バイオマーカー
• マイクロバイオームバイオマーカー
• 自己抗体バイオマーカー
• 細胞外小胞バイオマーカー

第7章 地域別・国別分析

• 世界の個別化医療バイオマーカー市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の個別化医療バイオマーカー市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 個別化医療バイオマーカー市場：競合情勢
• 個別化医療バイオマーカー市場：企業プロファイル
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck KGaA
• GE Healthcare
• Laboratory Corporation of America Holdings（LabCorp）
• Agilent Technologies Inc.
• Hologic Inc.
• Illumina Inc.
• PerkinElmer Inc.
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• DH Life Sciences LLC
• Myriad Genetics Inc.
• Guardant Health Inc.
• Cardiff Oncology Inc.
• 23andMe Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 個別化医療バイオマーカー市場2029年：新たな機会を提供する国
• 個別化医療バイオマーカー市場2029年：新たな機会を提供するセグメント
• 個別化医療バイオマーカー市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Personalized medicine biomarkers are specific biological indicators that customize medical treatments for individual patients based on their unique genetic, molecular, or physiological characteristics. These biomarkers help predict how a patient will respond to a particular drug, allowing healthcare providers to select the most effective and safest treatment options.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of biomarkers in personalized medicine include genomic, proteomic, metabolic, and other types. Genomic biomarkers refer to specific genes or genetic mutations that provide insights into how diseases develop and progress in individuals. These biomarkers are used for a variety of disease indications, such as oncology, neurology, diabetes, autoimmune diseases, cardiology, and more. They serve various purposes, including early detection or screening, diagnosis, treatment selection, and monitoring. Personalized medicine biomarkers are utilized by a range of end users, including hospitals and clinics, pharmaceutical and biotechnology companies, diagnostic laboratories, and others.

The personalized medicine biomarkers market research report is one of a series of new reports from The Business Research Company that provides personalized medicine biomarkers market statistics, including personalized medicine biomarkers industry global market size, regional shares, competitors with a personalized medicine biomarkers market share, detailed personalized medicine biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the personalized medicine biomarkers industry. This personalized medicine biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The personalized medicine biomarkers market size has grown rapidly in recent years. It will grow from $22.85 billion in 2024 to $26.98 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases, the rising adoption of companion diagnostics, growing investment in biomarker research, a heightened focus on early diagnosis and preventive healthcare, and regulatory support for biomarker-based therapies.

The personalized medicine biomarkers market size is expected to see rapid growth in the next few years. It will grow to $51.53 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth during the forecast period can be attributed to the expanding applications of biomarkers in precision oncology, rising demand for targeted therapies, a growing focus on early disease detection, increasing consumer demand for personalized approaches, and supportive government policies and funding. Key trends expected in the forecast period include the adoption of a multi-omics approach for biomarker identification, the development of liquid biopsy-based biomarkers, a growing use of digital biomarkers, the integration of AI and machine learning in biomarker discovery, and the expansion of real-world evidence in biomarker validation.

The growing prevalence of chronic diseases is expected to drive substantial growth in the personalized medicine biomarkers market. Chronic diseases are long-term conditions that develop gradually and persist for extended periods, often requiring ongoing medical care or affecting daily activities. The rise in chronic diseases is largely attributed to unhealthy lifestyle choices, poor diets, insufficient physical activity, and high stress levels. Personalized medicine biomarkers play a key role in managing these conditions by tailoring treatments based on individual genetic and molecular profiles. These biomarkers help identify the most effective therapies, predict disease progression, and minimize adverse effects. For example, the World Health Organization (WHO) predicts that by 2050, the number of new cancer cases will exceed 35 million, a 77% increase from 2022. This escalating prevalence of chronic diseases is accelerating demand for personalized medicine biomarkers.

Companies in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals to enhance product credibility, expand their market reach, and improve patient outcomes. Regulatory approvals are essential as they ensure that medical products, treatments, or technologies meet safety, efficacy, and quality standards. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received FDA approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval represents a significant milestone in precision oncology, improving the speed and accuracy of treatment selection and enhancing personalized care for cancer patients.

In February 2025, Renovaro Inc., a US-based biotechnology firm, merged with BioSymetrics Inc. to boost AI-driven biomarker discovery and precision medicine initiatives. The merger is set to enhance drug development and facilitate the creation of personalized treatment strategies, particularly for complex diseases. BioSymetrics Inc., a Canada-based company specializing in phenomics-driven drug discovery, uses machine learning to integrate clinical and experimental data, advancing the field of precision medicine.

Major players in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in personalized medicine biomarkers report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the personalized medicine biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The personalized medicine biomarkers market consists of sales of biomarker-based diagnostic kits, reagents, testing platforms, epigenetic biomarkers, companion diagnostics, predictive biomarkers, prognostic biomarkers, and multi-omics biomarkers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Personalized Medicine Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on personalized medicine biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for personalized medicine biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The personalized medicine biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biomarker Type: Genomic; Proteomics; Metabolic; Other Biomarker Types
• 2) By Disease Indication: Oncology; Neurology; Diabetes; Autoimmune Diseases; Cardiology; Other Indications
• 3) By Application: Early Detection Or Screening; Diagnosis; Treatment Selection; Monitoring
• 4) By End Use: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Diagnostic Labs; Other End Users
• Subsegments:
• 1) By Genomic: Single Nucleotide Polymorphisms (SNPs); Copy Number Variations (CNVs); Gene Expression Biomarkers; Epigenetic Biomarkers
• 2) By Proteomics: Protein Expression Biomarkers; Post-Translational Modification (PTM) Biomarkers; Protein-Protein Interaction Biomarkers; Enzyme Activity Biomarkers
• 3) By Metabolic: Lipid Biomarkers; Amino Acid Biomarkers; Carbohydrate Biomarkers; Hormone Biomarkers
• 4) By Other Biomarker Types: Inflammatory Biomarkers; Microbiome Biomarkers; Autoantibody Biomarkers; Extracellular Vesicle Biomarkers
• Companies Mentioned: AbbVie Inc.; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Abbott Laboratories; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Personalized Medicine Biomarkers Market Characteristics

3. Personalized Medicine Biomarkers Market Trends And Strategies

4. Personalized Medicine Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Personalized Medicine Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Personalized Medicine Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Personalized Medicine Biomarkers Market Growth Rate Analysis
• 5.4. Global Personalized Medicine Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Personalized Medicine Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Personalized Medicine Biomarkers Total Addressable Market (TAM)

6. Personalized Medicine Biomarkers Market Segmentation

• 6.1. Global Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genomic
• Proteomics
• Metabolic
• Other Biomarker Types
• 6.2. Global Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Neurology
• Diabetes
• Autoimmune Diseases
• Cardiology
• Other Indications
• 6.3. Global Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Detection Or Screening
• Diagnosis
• Treatment Selection
• Monitoring
• 6.4. Global Personalized Medicine Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Pharmaceutical And Biotechnology Companies
• Diagnostic Labs
• Other End Users
• 6.5. Global Personalized Medicine Biomarkers Market, Sub-Segmentation Of Genomic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Nucleotide Polymorphisms (SNPs)
• Copy Number Variations (CNVs)
• Gene Expression Biomarkers
• Epigenetic Biomarkers
• 6.6. Global Personalized Medicine Biomarkers Market, Sub-Segmentation Of Proteomics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Protein Expression Biomarkers
• Post-Translational Modification (PTM) Biomarkers
• Protein-Protein Interaction Biomarkers
• Enzyme Activity Biomarkers
• 6.7. Global Personalized Medicine Biomarkers Market, Sub-Segmentation Of Metabolic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipid Biomarkers
• Amino Acid Biomarkers
• Carbohydrate Biomarkers
• Hormone Biomarkers
• 6.8. Global Personalized Medicine Biomarkers Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inflammatory Biomarkers
• Microbiome Biomarkers
• Autoantibody Biomarkers
• Extracellular Vesicle Biomarkers

7. Personalized Medicine Biomarkers Market Regional And Country Analysis

• 7.1. Global Personalized Medicine Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Personalized Medicine Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Personalized Medicine Biomarkers Market

• 8.1. Asia-Pacific Personalized Medicine Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Personalized Medicine Biomarkers Market

• 9.1. China Personalized Medicine Biomarkers Market Overview
• 9.2. China Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Personalized Medicine Biomarkers Market

• 10.1. India Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Personalized Medicine Biomarkers Market

• 11.1. Japan Personalized Medicine Biomarkers Market Overview
• 11.2. Japan Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Personalized Medicine Biomarkers Market

• 12.1. Australia Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Personalized Medicine Biomarkers Market

• 13.1. Indonesia Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Personalized Medicine Biomarkers Market

• 14.1. South Korea Personalized Medicine Biomarkers Market Overview
• 14.2. South Korea Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Personalized Medicine Biomarkers Market

• 15.1. Western Europe Personalized Medicine Biomarkers Market Overview
• 15.2. Western Europe Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Personalized Medicine Biomarkers Market

• 16.1. UK Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Personalized Medicine Biomarkers Market

• 17.1. Germany Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Personalized Medicine Biomarkers Market

• 18.1. France Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Personalized Medicine Biomarkers Market

• 19.1. Italy Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Personalized Medicine Biomarkers Market

• 20.1. Spain Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Personalized Medicine Biomarkers Market

• 21.1. Eastern Europe Personalized Medicine Biomarkers Market Overview
• 21.2. Eastern Europe Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Personalized Medicine Biomarkers Market

• 22.1. Russia Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Personalized Medicine Biomarkers Market

• 23.1. North America Personalized Medicine Biomarkers Market Overview
• 23.2. North America Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Personalized Medicine Biomarkers Market

• 24.1. USA Personalized Medicine Biomarkers Market Overview
• 24.2. USA Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Personalized Medicine Biomarkers Market

• 25.1. Canada Personalized Medicine Biomarkers Market Overview
• 25.2. Canada Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Personalized Medicine Biomarkers Market

• 26.1. South America Personalized Medicine Biomarkers Market Overview
• 26.2. South America Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Personalized Medicine Biomarkers Market

• 27.1. Brazil Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Personalized Medicine Biomarkers Market

• 28.1. Middle East Personalized Medicine Biomarkers Market Overview
• 28.2. Middle East Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Personalized Medicine Biomarkers Market

• 29.1. Africa Personalized Medicine Biomarkers Market Overview
• 29.2. Africa Personalized Medicine Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Personalized Medicine Biomarkers Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Personalized Medicine Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Personalized Medicine Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Personalized Medicine Biomarkers Market Competitive Landscape
• 30.2. Personalized Medicine Biomarkers Market Company Profiles
  • 30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Personalized Medicine Biomarkers Market Other Major And Innovative Companies

• 31.1. Merck KGaA
• 31.2. GE Healthcare
• 31.3. Laboratory Corporation of America Holdings (LabCorp)
• 31.4. Agilent Technologies Inc.
• 31.5. Hologic Inc.
• 31.6. Illumina Inc.
• 31.7. PerkinElmer Inc.
• 31.8. Beckman Coulter Inc.
• 31.9. Bio-Rad Laboratories Inc.
• 31.10. QIAGEN N.V.
• 31.11. DH Life Sciences LLC
• 31.12. Myriad Genetics Inc.
• 31.13. Guardant Health Inc.
• 31.14. Cardiff Oncology Inc.
• 31.15. 23andMe Inc.

32. Global Personalized Medicine Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Personalized Medicine Biomarkers Market

34. Recent Developments In The Personalized Medicine Biomarkers Market

35. Personalized Medicine Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Personalized Medicine Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Personalized Medicine Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Personalized Medicine Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34923_Personalized_Medicine_Biomarkers_GMR_2025